Fabrice Soncin

Centre National de la Recherche Scientifique — France

Biochemistry, Genetics and Molecular Biology · Life Sciences

33h-index3.7kcitations133works0.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Angiogenesis and VEGF in Cancer(34), Hippo pathway signaling and YAP/TAZ(32), Cell Adhesion Molecules Research(18), 3D Printing in Biomedical Research(12), Cancer-related gene regulation(10)

Publications133 total

Novel Diffuse Midline Glioma‐on‐Chip Recapitulating Tumor Biophysical Microenvironment to Assess the Heterogeneity of Response to Therapies
Small·2025Open Access
Exploring the role of readthrough-inducing molecule 2,6-diaminopurine to increase immune response against cancer cells
Molecular Therapy·2025· 1 citedOpen Access
Engineering a microfluidic platform for cell extravasation monitoring and downstream characterization of disseminated cells
Biomicrofluidics·2025Open Access
Bioengineering a Patient‐Derived Vascularized Lung Tumor‐on‐Chip Model to Decipher Immunomodulation by the Endothelium
Advanced Healthcare Materials·2025· 3 citedOpen Access
Establishment and characterization of a tumor-on-a-chip mimicking the DIPG tumor microenvironment
SPIRE - Sciences Po Institutional REpository·2024
Coculture model of a liver sinusoidal endothelial cell barrier and HepG2/C3a spheroids-on-chip in an advanced fluidic platform
Journal of Bioscience and Bioengineering·2023· 6 citedOpen Access
Investigation of the metabolomic crosstalk between liver sinusoidal endothelial cells and hepatocytes exposed to paracetamol using organ-on-chip technology
Toxicology·2023· 10 citedOpen Access
Genes Involved in miRNA Biogenesis Are Not Downregulated in SARS-CoV-2 Infection
Viruses·2023· 4 citedOpen Access
Développement d'une "métastase-sur-puce" pour l'étude de l'extravasation au cours du processus métastatique du cancer du sein.
SPIRE - Sciences Po Institutional REpository·2023Open Access
Figure S2: Depletion of RASSF1A alone or with RASSF1C results in disappearance of tight junctions and decrease of adherens junction, replaced by diffuse adherent junctions. from RASSF1A Suppresses the Invasion and Metastatic Potential of Human Non–Small Cell Lung Cancer Cells by Inhibiting YAP Activation through the GEF-H1/RhoB Pathway
2023Open Access
Figure S8: RhoA activity is not influenced by RASSF1A depletion whereas constitutive activation of a Rho activity by Narciclasine still impairs RASSF1A-induced invasion. from RASSF1A Suppresses the Invasion and Metastatic Potential of Human Non–Small Cell Lung Cancer Cells by Inhibiting YAP Activation through the GEF-H1/RhoB Pathway
2023Open Access
Figure S7: Time-course YAP cytoplasmic-nuclear shuttling upon RASSF1A depletion. from RASSF1A Suppresses the Invasion and Metastatic Potential of Human Non–Small Cell Lung Cancer Cells by Inhibiting YAP Activation through the GEF-H1/RhoB Pathway
2023Open Access
Table S5 from RASSF1A Suppresses the Invasion and Metastatic Potential of Human Non–Small Cell Lung Cancer Cells by Inhibiting YAP Activation through the GEF-H1/RhoB Pathway
2023Open Access
Figure S1: Scheme of RASSF1 splicing isoforms and localization annealing regions of siRNAs and shRNAs used. from RASSF1A Suppresses the Invasion and Metastatic Potential of Human Non–Small Cell Lung Cancer Cells by Inhibiting YAP Activation through the GEF-H1/RhoB Pathway
2023Open Access
Table S4 from RASSF1A Suppresses the Invasion and Metastatic Potential of Human Non–Small Cell Lung Cancer Cells by Inhibiting YAP Activation through the GEF-H1/RhoB Pathway
2023Open Access
Figure S4: trans-endothelial invasion, enhanced-migration and growth in soft agar upon RASSF1A depletion in 4 transformed and untransformed epithelial bronchial cell lines. from RASSF1A Suppresses the Invasion and Metastatic Potential of Human Non–Small Cell Lung Cancer Cells by Inhibiting YAP Activation through the GEF-H1/RhoB Pathway
2023Open Access
Table S1 from RASSF1A Suppresses the Invasion and Metastatic Potential of Human Non–Small Cell Lung Cancer Cells by Inhibiting YAP Activation through the GEF-H1/RhoB Pathway
2023Open Access
Figure S2: Depletion of RASSF1A alone or with RASSF1C results in disappearance of tight junctions and decrease of adherens junction, replaced by diffuse adherent junctions. from RASSF1A Suppresses the Invasion and Metastatic Potential of Human Non–Small Cell Lung Cancer Cells by Inhibiting YAP Activation through the GEF-H1/RhoB Pathway
2023Open Access
Table S4 from RASSF1A Suppresses the Invasion and Metastatic Potential of Human Non–Small Cell Lung Cancer Cells by Inhibiting YAP Activation through the GEF-H1/RhoB Pathway
2023Open Access
Figure S8: RhoA activity is not influenced by RASSF1A depletion whereas constitutive activation of a Rho activity by Narciclasine still impairs RASSF1A-induced invasion. from RASSF1A Suppresses the Invasion and Metastatic Potential of Human Non–Small Cell Lung Cancer Cells by Inhibiting YAP Activation through the GEF-H1/RhoB Pathway
2023Open Access
page 1 of 7Next →

Frequent Co-authors

Virginie Mattot(15), Stuart K. Calderwood(7), Etienne Lelièvre(7), Gaëlle Villain(6), Bertrand Caëtano(6), Sébastien Pinte(5), Mary Ann Stevenson(4), Boyang Chu(3), Josette Badet(3), Chantal Samson(3), Marie‐Christine Baranzelli(3), Jacques Bonneterre(3), Alexandra Le Bras(3), Frédéric Lionneton(3), Tanja Rothhammer(2), Ina Poser(2), Anja‐Katrin Bosserhoff(2), Jean‐Dominique Guitton(2), Terence Cartwright(2), Denis Barritault(2)